Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis DURECT Corp DRRX

Healthcare
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for... see more

Opinion & Analysis (NDAQ:DRRX)

    Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

    Streetwise Reports July 24, 2019

    Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

    Streetwise Reports March 14, 2019

    DURECT Receives Return on Schizophrenia Drug Approval

    Streetwise Reports October 4, 2018

    Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug

    Streetwise Reports August 2, 2018

    Progress in pain control and liver disease programs spurs rise in company's rating

    The Life Sciences Report July 19, 2017

    Analysts take note as small-cap biotech completes early enrollment for Phase 3 trial

    The Life Sciences Report July 6, 2017

    Small-caps rushing to fill the NASH treatment pipeline

    The Life Sciences Report May 25, 2017

    DURECT and Sandoz ink $293 million deal for POSIMIR

    The Life Sciences Report May 11, 2017

    Trial results set up DURECT Corp. for 'exciting year'

    The Life Sciences Report April 27, 2017

    Many paths to success with DURECT's pipeline

    The Life Sciences Report March 30, 2017

    Why the election is not as relevant to drug stocks as you might believe

    The Life Sciences Report November 4, 2016

    Analysts keep focus on DURECT's DUR-928

    The Life Sciences Report October 7, 2016

    Three shots on goal in Q4/16 for DURECT Corp.

    The Life Sciences Report September 8, 2016

    Durect's abuse-deterrent opioid poised for FDA approval

    The Life Sciences Report July 14, 2016

    Drug pricing, presidential politics, and three biotechs with promise

    The Life Sciences Report April 13, 2016

    From acorns mighty trees can grow: Laidlaw's Jim Molloy on budding small-cap biotechs

    The Life Sciences Report March 16, 2016

    The Trader’s Edge: Life in the TSX Venture, Gold Miner Turn?

    Tyler Bollhorn June 25, 2014